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The Problem in America
An estimated 14-15 million people in the United States have
diabetes mellitus, and greater than 90% have non-insulin dependent
diabetes mellitus (NIDDM) or Type II Diabetes. One-half of the
NIDDM cases are undiagnosed. Moreover, when diagnosed, NIDDM
has probably been present for 4 to 7 years prior to diagnosis, based
on the presence of long-term complications at the time of diagnosis.
Diabetes prevalence has increased dramatically in the United States
over the past 30 years by approximately 50 % every 7 years. The
large increase is probably due to a shift in the age of the population
as well as accurate ascertainment of disease. In the past decade,
diabetes incidence in the United States has stabilized (40% increase
since 1980), and is presently estimated at 650,000 new cases per
year.’ However, the incidence worldwide and especially in the
developing countries is steadily rising. The World Health Organi
zation (WHO) has concluded that the “apparent epidemic of diabe
tes occurring worldwide is strongly related to lifestyle and eco
nomic changes”.
Current data from the Centers for Disease Control and Prevention
and the National Center for Health Statistics reveal the staggering
impact of diabetes and its complications in the United States.
Diabetes is among the 10 leading causes of death, the underlying
cause in over 40,000 deaths per year, and a contributing cause in
perhaps another 30,000 deaths.2The majority of adults with NIDDM
die from macrovascular disease which includes cardiovascular,
cerebrovascular, or peripheral vascular disease. Among deaths
related to diabetes, cardiovascluar disease is the cause of more than
80,000 cases per year.3 Diabetes is the primary diagnosis in almost
500,000 hospital discharges per year and the secondary diagnosis in
almost 3 million hospitalizations in a year.
Diagnosed NIDDM is only the tip of the iceberg of an epidemic
of glucose intolerance. Impaired glucose tolerance or IGT is even
more prevalent than NIDDM. In addition to being a major risk factor
for the development ofNIDDM, IGT is associated with an increased
risk for macrovascular disease. IGT is not associated with diabetes-
specific complications of microvascular disease which includes
retinopathy, nephropathy, and neuropathy. Among adults 20-74
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years of age in the United States, estimates in 1990 and in accor
dance with WHO criteria, approximately 18% have some form of
glucose intolerance (7% with NIDDM and 11% with IGT).’ The
major impact of aging is evidenced by the 42% prevalence of IGT
and NIDDM in the population between 65 and 74 years. The risk of
abnormal glucose tolerance is greatly increased in minority popula
tions such as African Americans, Hispanic Americans, American
Indians, Asian and Pacific Island Americans. On the basis of the
continued growth of the fraction of the United States population
older than 65 years, and of the ethnic and racial groups at particu
larly high risk of developing NIDDM and IGT, the overall preva
lence of glucose intolerance is feared to increase in the next decade.
The Epidemic Among Hawaiians
In 1985, a Medical Task Force Report, researched and prepared by
E Ola Mau, a consortium of Native Hawaiian Health Professionals,
reported “From 1910 to 1980, in every major disease category, pure
Hawaiians had the highest mortality rate. Rates for part Hawaiians
were intermediate or similar to those for all races”.4This report led
to the enactment of the Native Hawaiian Health Care Act signed into
law by President Ronald Reagan in 1988 which provides for
resources to improve the health status of Hawaiians
The comparison of diabetes mellitus rates among Native Hawai
ians and other races in Hawaii had been initially reported by Sloan
in 1963.° Of 38,103 adults employed on Oahu, pure Hawaiians had
a prevalence rate for diabetes of 48.8 per 1000 individuals as
compared to a rate of 18.4 per thousand of all races. Part Hawaiians
were found to have an intermediate rate of 26.6 diabetics per
thousand. In 1966, a study conducted on the island of Niihau had
identified 8 diabetics among 60 pure Hawaiian men, a prevalence
rate of 12%.6 The Molokai Heart Study had examined 247 adult
Hawaiians between the ages of 20 to 59 on the island of Molokai,
and reported a diabetes prevalence rate of 10% in women and 12%
in men.7 Most recently, the Native Hawaiian Health Research
Project, a descriptive epidemiologic study of diabetes and heart
disease risk factors among Native Hawaiians, have reported the
highest prevalence rate of diabetes to date. In 1993, this University
of Hawaii sponsored project examined with a 2 hour Oral Glucose
Tolerance Test (OGTT) 177 adult Hawaiians over the age of 30
years residing in North Kohala. A diabetes prevalence rate of 18 %
by WHO criteria was observed.8The combined results of all these
studies clearly document the increasing rate of diabetes among
Native Hawaiians over the past 30 years. As compared to the
national trend, the prevalence rate is higher, and appears to be
disproportionately increasing over 3 decades (Figure 1).
The Native Hawaiian Health Research Project has also reported
an IGT rate of 16 % (Fasting Blood Glucose < 140 mg/dl, and a 2
hour value between 140-199 mg/dl during an OGTT, WHO crite
ria), the first assessment of IGT prevalence among Hawaiians. The
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Fig 1.—Prevalence estimates of diabetes mellitUs in Native
Hawaiians and the general U.S. population from 1960-1996.
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Estimate of Native Hawaiian Diabetes Prevalence
IGT rate appears to equal the rate of diabetes, which
places the rate of glucose intolerance among Hawaiians
at 34 % or one in three adult Hawaiians over the age of
30. This rate of glucose intolerance is alarmingly nearly
twice the rate of 18 % observed for the general United
States population. Importantly, this combined rate of
NIDDM and IGT among Hawaiians significantly con
tributes to increased CVD risk and may remain the
primary factor responsible for the observed increased
heart disease morbidity and mortality. The identification
of the IGT population offers a glimpse of future NIDDM
prevalence and the opportunity to intervene.
In Hawaii, approximately 8% of the State population is
estimated to have diabetes. Thus, in a State of about a
million people, about 80,000 individuals have diabetes,
primarily adults with NIDDM. Among Hawaiians, based
on the recent data from the North Kohala community,
approximately one of five adults have diabetes. The State
ofHawaii’s adult Hawaiian population over the age of 30
is estimated to be 100,000 or 50% of the total population
of 200,000 people.9Thus, 20,000 adult Hawaiians have
diabetes which account for approximately one fourth of
the State’s diabetic population. This is clearly a dispro
portionate and unfortunate representation. In addition,
among dialysis patients with diabetes, over 40% are
Native Hawaiians which suggest an increased rate of
diabetic complications among Hawaii’s indigenous popu
lation.
Efforts to Prevent Diabetes and Diabetes-
Related Complications
Despite the putative role for genetic factors in its
developement, NIDDM may be largely preventable.
Studies have demonstrated the adverse consequences of
decreased physical activity and obesity, and the risk for
developing NIDDM. These observations support the03-5982-1
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role ofpotentially reversible factors in the development of diabetes.
Among the most important factors associated with increased risk of
developing NIDDM are obesity, age greater than 40 years, a history
of IGT or gestational diabetes mellitus (GDM), a positive family
history of NIDDM, and being a member of a minority population.
These many risk factors are also associated with IGT. Approxi
mately, 30-40 % of IGT individuals progress on to NTDDM over a
5-10 year period. The rate of progression is esitmated to be approxi
mately 5 % per year and may be greater among higher risk popula
tions. Women with GDM also have an approximate 10 year risk of
30-40 % for developing NTDDM. In recently industrialized coun
tries and in migrating populations that previously had a low preva
lence of NIDDM, changes in diet and an increasingly sedentary
lifestyle, with consequent increase in body mass, have been associ
ated with the development of NJDDM. It is apparent that the
“epidemic of diabetes” may worsen in the future, and the need to
intervene is overwhelming.
Still, we can take heart in a number ofadvances and new initiatives
that may reduce the rate of NIDDM and diabetes-related complica
tions in the future. The Diabetes Control and Complications Trial,
a landmark study reported in 1993, has shown that lower blood
glucose levels either prevent or decrease diabetic eye and kidney
diseases.1°Subsequently, many more studies have come to empha
size the relationship of lower blood glucose concentrations and
reduced rates of complications among all diabetics. Thus, it is
apparent that measures to improve blood glucose control among
Hawaiians and all races with diabetes should reduce long-term
complications. There are now many new options for the treatment
of diabetes which includes new anti-hyperglycemic agents, multi
disciplinary approaches to diabetes care, and easier means to
monitor blood sugars and disease progression. However, the role of
the patient to be compliant and be an active member of the diabetes
management team cannot be over emphasized, and justifies major
efforts to enhance diabetes education for these patients. Lastly, the
large at-risk population of JOT individuals are offered a research
program to determine if NIDDM can be prevented. The Diabetes
Prevention Program is a five to seven year multi-center nationwide
study to assess whether interventions of lifestyle changes and
phannacologic therapy can prevent diabetes among JOT individu
als. As investigators in this Program, we seek our colleague’s
assistance in identifying these lOT individuals and working with us
to possibly reduce the high prevalence of diabetes among Hawai
ians and in the State of Hawaii.
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